Zaprinast (M&B 22948) is a selective inhibitor of cGMP-selective Phosphodiesterase ( PDE5 ) . Zaprinast causes a significant increase in cGMP levels in myocytes. Zaprinast is a G protein-coupled receptor 35 ( GPR35 ) agonist which activates rat GPR35 strongly and activates human GPR35 moderately. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects.